Search

Furosemide

[L7961] It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body.

Camphor monobromide

Oxcarbazepine

Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activ...

Crizanlizumab

It was developed by Novartis and was granted FDA approval on November 15, 2019.

Enoxacin

A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

Eugenol

Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves.

Pheniprazine

Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.

Norgestimate

[A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects.

Clomifene

A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.

Mobocertinib

It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic